Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Moderna Jumps On Unexpected First-Quarter Profit Amid Plummeting Covid Sales
Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting
https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-Phase-12-Data-on-mRNA-3927-an-Investigational-mRNA-Therapy-for-Propionic-Acidemia-PA-to-be-Presented-at-the-2023-ASGCT-Annual-Meeting/default.aspx
"We are pleased to expand our footprint into the Philipines by establishing an Enterprise Solutions Hub and commercial operations. The Philippines has a critical mix of talent and global business service expertise, which makes it an excellent location to scale efficiently and provide regional support," said Stéphane Bancel, Chief Executive Officer of Moderna."The Asia Pacific region is integral to Moderna's business, with established subsidiaries in Australia, Hong Kong, Japan, Singapore, South Korea, and Taiwan. We look forward to further solidifying our presence. The addition of the Philippines site completes our strategy to provide regional solutions across the business, complementing our existing locations in Atlanta, Georgia, which services the Americas, and Warsaw, Poland, which covers Europe, the Middle East, and Africa."
https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-Establishment-of-an-Enterprise-Solutions-Hub-and-Commercial-Operations-in-The-Philippines/default.aspx
shrimp for everyone!
Moderna looks to the future with latest campaign and a flashy new ad
Cathie Wood's ARK Innovation ETF buys shares of businesses that have the potential to change our world: $MRNA
https://www.fool.com/investing/2023/04/30/this-cathie-wood-stock-is-tanking-heres-why/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
winner$
the important thing is to believe not to hope!
Covid vaccine maker is sitting on $18bn and embarking on a host of ambitious projects:
https://www.ft.com/content/5fc71e17-541c-4fe8-a2cb-ae7d17917366?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev
For my second pick, I'm swinging for the fences with a long shot to surpass Berkshire Hathaway. Moderna is a biotech company that most people know for its COVID-19 vaccine.
However, the company's messenger RNA therapeutics and vaccines can potentially be used to treat other diseases. In fact, Moderna's chief medical officer, Dr. Paul Burton, recently noted that the company aims to produce vaccines targeting cancer, heart disease, and other serious diseases by 2030. If that prediction comes true, expect Moderna shares to skyrocket.
Before you know it, these three companies might surpass Berkshire Hathaway:
And Moderna shares will need to skyrocket if the company's market cap is going to exceed Berkshire Hathaway's. Today, Moderna has a market cap of $52.8 billion, ranking No. 304 among American companies. To catch Berkshire, Moderna would need to grow 14 times. That's a big ask, but effective treatments for life-threatening diseases like cancer and heart disease would be a game changer, not just for the company -- but for the world.
However, at present, those treatments remain out of reach, meaning Moderna will have to rely on other products to drive its revenue and earnings. Financially, the company remains healthy, with $18.9 billion in revenue and $9.4 billion in operating income over the last 12 months. Yet, with sales of its COVID vaccine waning, analysts expect revenue to decline by 60% in 2023 and a further 15% in 2024.
Needless to say, owning Moderna isn't for everyone. Like a power hitter at the plate, Moderna is swinging for the fences. Sometimes those hitters blast it out of the park; other times, they strike out.
I agree 1000%>>>>>>>>>>
https://www.fool.com/investing/2023/04/27/3-stocks-that-could-be-worth-more-than-berkshire-h/
I find value in your desperation....over thinking!
Florida surgeon general altered Covid-19 vaccine analysis to suggest higher risk for younger men:
https://edition.cnn.com/2023/04/25/health/florida-covid-vaccine-analysis-ladapo/index.html
Construction commences at Moderna Innovation and Technology Centre in the UK
https://www.harwellcampus.com/moderna-groundbreaking-at-harwell/
Moderna and IBM-
today announced an agreement under which Moderna will explore next generation technologies including quantum computing and artificial intelligence to advance and accelerate mRNA research and science.
https://investors.modernatx.com/news/news-details/2023/Moderna-and-IBM-to-Explore-Quantum-Computing-and-Generative-AI-for-mRNA-Science/default.aspx
RSV vaccine approval should be a top priority for the FDA.. I agree 100%
https://www.statnews.com/2023/04/19/rsv-vaccines-children-fda-approval/
“The profound observed reduction in the risk of recurrence-free survival suggests this combination may be a novel means of potentially extending the lives of patients with high-risk melanoma,” said Kyle Holen, a senior vice president and head of development, therapeutics and oncology at Moderna.
Globally, we are on track-
the results of the trial- which shows reduced rates of cancer recurrence after therapy, by 44%, and was 77% effective after 18 months, in combination with Merck's Keytruda, versus Keytruda alone.
But, on the flip side, "bears point to baseline imbalances between study arms, a small trial with a liberal threshold for statistical signal, and evolving standard-of-care in melanoma towards immunotherapy in the neo-adjuvant setting,"
$ the battle continues$
Yes as always!
the story continues-with phase 3 launch before year-end!
https://www.fiercebiotech.com/biotech/aacr-merck-moderna-plan-registrational-cancer-vax-trial-years-end
additional subgroup analysis data will be presented during a poster session on Tuesday, April 18-
Merck-Moderna vaccine helps reduce chances of skin cancer-
The new results found that 79 percent of participants who received the vaccine and Keytruda stayed cancer-free for 18 months compared to just 62 percent of people who only received Merck’s Keytruda. The companies also said that the results of Phase Two showed mild side effects with the vaccine, like fatigue, injection site pain or chills-
US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma
https://finance.yahoo.com/news/us-court-favors-moderna-covid-163701343.html
Moderna said it expects to see between $8 billion and $15 billion in sales from its Covid, RSV, flu and other respiratory vaccines in 2027.
The biotech company said it sees a corresponding operating profit in the range of $4 billion to $9 billion.
Moderna said it expects to file for full approval of its experimental RSV vaccine for adults ages 60 and older this quarter.
Moderna's mRNA flu shot struggles to prove its worth again in phase 3 trial.....relax!!!!!!
A preliminary analysis of immunogenicity from a subset of participants in the trial has also been completed, which showed that mRNA-1010 demonstrated geometric mean titer ratios suggesting it was more effective against both influenza A strains than an approved flu vaccine. However, when it came to both influenza B strains, the shot was only able to show “non-inferiority” to the competitor, Moderna said.
https://www.fiercebiotech.com/biotech/modernas-mrna-flu-shot-continues-struggle-prove-its-worth-phase-3-trials
$MRNA announced clinical and program updates this morning and noted that its second Phase 3 trial (P302) of its flu vaccine, mRNA-1010, did not meet the statistical threshold necessary to declare early success. The DSMB did not identify any safety concerns!
relax....They'll send the details in due course.
MODERNA ANNOUNCES CLINICAL AND PROGRAM UPDATES AT 4TH VACCINES DAY:
https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-Clinical-and-Program-Updates-at-4th-Vaccines-Day/default.aspx
Cancer and heart disease vaccines ‘ready by end of the decade:
Dr Paul Burton, the chief medical officer of pharmaceutical company Moderna, said he believes the firm will be able to offer such treatments for “all sorts of disease areas” in as little as five years.
https://www.theguardian.com/society/2023/apr/07/cancer-and-heart-disease-vaccines-ready-by-end-of-the-decade
MRNA-4157/V940, AN INVESTIGATIONAL PERSONALIZED MRNA CANCER VACCINE, IN COMBINATION WITH KEYTRUDA(R) (PEMBROLIZUMAB), RECEIVES PRIME SCHEME DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR ADJUVANT TREATMENT OF PATIENTS WITH HIGH-RISK STAGE III/IV MELANOMA FOLLOWING COMPLETE RESECTION
https://investors.modernatx.com/news/news-details/2023/MRNA-4157V940-an-Investigational-Personalized-MRNA-Cancer-Vaccine-in-Combination-With-KeytrudaR-Pembrolizumab-Receives-Prime-Scheme-Designation-From-the-European-Medicines-Agency-for-Adjuvant-Treatment-of-Patients-With-High-Risk-Stage-IIIIV-Melanoma-/default.aspx
First Citizens Bank & Trust Co. Increases Investment in Moderna Inc. Amid Growing Confidence in mRNA-based Medicine
First Citizens Bank & Trust Co. has increased its position in Moderna, Inc., investing a further $2,177,000 into the revolutionary healthcare company. Moderna’s approach to medicine is based on messenger ribonucleic acid (mRNA), which makes breakthroughs in areas such as prophylactic vaccines, cancer treatment and regenerative therapeutics possible. The investment by First Citizens Bank & Trust Co. highlights their confidence in the innovative capacity of Moderna’s work.
This board has plenty of FUD & Tin Foil Hats
I
MODERNA FINALIZES AGREEMENT WITH THE GOVERNMENT OF THE REPUBLIC OF KENYA TO ESTABLISH AN MRNA MANUFACTURING FACILITY
in partnership with the Government of the Republic of Kenya, Moderna will build a state-of-the-art mRNA facility in Kenya to produce up to 500 million doses of vaccines each year. The Company expects the new facility to enable drug substance and drug product manufacturing for Kenya and the African continent. In addition, this facility will have surge capacity to rapidly scale and respond to public health emergencies on the continent and around the world.
Moderna is committed to advancing into clinical studies a portfolio of 15 vaccine programs targeting emerging or neglected infectious diseases by 2025, advancing vaccines that address current diseases of significant impact to low- and middle-income countries, and those that prepare for Disease X. Moderna will prioritize development efforts against pathogens identified as persistent global health threats, including HIV, tuberculosis (TB) and malaria, neglected tropical diseases and the priority pathogens of the World Health Organization and the Coalition for Epidemic Preparedness Innovations.
With this agreement, Moderna has commitments to establish mRNA manufacturing facilities in Kenya, the United States, Canada, Australia, and the United Kingdom
https://investors.modernatx.com/news/news-details/2023/Moderna-Finalizes-Agreement-with-the-Government-of-the-Republic-of-Kenya-to-Establish-an-mRNA-Manufacturing-Facility/default.aspx
Johnson & Johnson ducked out of the RSV vaccine race Wednesday, leaving Pfizer, GSK and Moderna to duke it out.
https://www.fiercebiotech.com/biotech/jj-scraps-phase-3-rsv-vaccine-infectious-disease-overhaul-continues
Moderna predicts the post-pandemic market will follow that of the flu. In the U.S. alone, about half of Americans go for flu shots
Moderna's pipeline includes more than 40 programs. Today, three candidates outside the coronavirus program are in phase 3 trials -- and close to the finish line. These are vaccine candidates for respiratory syncytial virus (RSV), cytomegalovirus (CMV), and flu. Moderna aims to file for regulatory approval of the RSV candidate in the first half of this year.
The company recently reported positive data from a phase 2 trial of its personalized cancer vaccine combined with Merck's Keytruda. In fact, the U.S. Food and Drug Administration even granted the combination a breakthrough therapy designation. This is meant to accelerate the development of promising products for serious conditions.
the future looks bright, with many huge potential growth drivers right around the corner!!!!!!
MODERNA TO HOST FOURTH ANNUAL VIRTUAL VACCINES DAY ON APRIL 11, 2023
news coming.......
In a sceptical era, understand this: vaccines do work - and our children need them:
in 1959, at the age of 29, the promising England footballer Jeff Hall died of polio. His death sent shock waves across Britain, and caused an immediate change in attitudes towards vaccination, from complacency to a sudden rush to clinics. A polio vaccine had been available for three years, but takeup was low. After Hall’s death, the demand was so high that vaccines had to be flown in from the US. As the Daily Express put it: “In the past 10 years over 3,000 people have died of polio in England and Wales. But it took the death of one footballer to get [people] pouring into the clinics.” More than half a century later, we may be returning to complacency when it comes to getting children vaccinated.
https://www.theguardian.com/commentisfree/2023/mar/27/vaccines-work-children-covid-decline-england
Moderna's gene therapy expansion picks up pace with $76M upfront Generation Bio collab
It's your fantasy, not mine.
The future is moving quickly....
How mRNA vaccines could target everything from cancer to the plague-
https://nypost.com/2023/03/25/how-mrna-vaccines-could-soon-target-cancer-the-plague/
Moderna CEO brazenly defends 400% COVID shot price hike, downplays NIH’s role
https://arstechnica.com/science/2023/03/moderna-ceo-says-us-govt-got-covid-shots-at-discount-ahead-of-400-price-hike/
FDA May Authorize Additional Covid-19 Booster Shots
Agency officials could make the decision on clearing another round for people at high risk within a few weeks
https://www.wsj.com/articles/fda-may-authorize-additional-covid-19-booster-shots-c85c0672
No good treatment goes unpunished for pharmaceutical companies these days, and Bernie Sanders will offer another example on Wednesday when he holds a political show trial of Moderna CEO Stéphane Bancel. His offense? Cooperating with the government to produce life-saving Covid vaccines.
The subject of the Vermont Senator’s hearing is Moderna’s plan to quadruple the price of its Covid vaccine to $110 to $130 per dose when U.S. government purchases stop. Pfizer has said it will charge a similar price after vaccines move to the commercial market, which is expected later this year.
But Mr. Sanders is specifically targeting Mr. Bancel because his company worked with the Trump Administration’s Operation Warp Speed (OWS) to accelerate its vaccine development. Mr. Bancel apparently should have known better than to work with the government.
Early in the Covid pandemic, Moderna received $900 million from OWS for trials to test its mRNA vaccine in partnership with the National Institutes of Health. Pfizer chose to go it alone because “when you get money from someone, that always comes with strings,” as CEO Albert Bourla explained in September 2020. No kidding.
Mr. Sanders claims that taxpayers paid to develop Moderna’s Covid vaccine, and the government thus should be able to dictate its price. That’s nonsense. Before the pandemic, Moderna developed its novel mRNA platform with $3.8 billion in private investment. In spring 2020, it raised another $1.3 billion in private capital to scale up manufacturing.
If not for the Moderna-OWS cooperation, the vaccine rollout would have been much slower. Moderna’s vaccine has proven more durable and protective against severe illness than Pfizer’s in real-world studies. Yet the Administration has consistently paid Pfizer $3 to $4 more per dose. As a result, Pfizer has received more than a billion dollars more from the government than Moderna.
Yet progressives are targeting Moderna as “a poster child for corporate greed,” to quote Mr. Sanders, because they believe this advances their view that pharma companies profit from government innovation and support. The truth is closer to the opposite. The government and public benefit from Moderna’s billions of dollars spent on research and development.
White House spokesperson Karine Jean-Pierre piled on by claiming Moderna’s price hike is “hard to justify” even as Biden officials hail the benefits of Covid vaccines and boosters. If they are as effective as public-health officials say, then the benefits from reducing hospitalizations among the elderly would more than exceed the new higher price.
Taxpayers were getting a bargain under the OWS contract that paid Moderna about $15 a dose. Even after the vaccine transitions to the commercial market, Moderna’s price will be lower than for such vaccines as GSK’s shingles shot ($183) or Merck’s pneumonia vaccine ($216), according to Centers for Disease Control and Prevention data.
Under the Affordable Care Act, Americans with private insurance won’t have to pay a penny out-of-pocket for the vaccines. Moderna will also offer free vaccines to the uninsured. So what’s the problem? Moderna will profit from its innovation. Oh no! Worse, Moderna’s profits will fund trials of other vaccines in development, including for cancer.
Life-saving vaccines and treatments undermine the political narrative that pharmaceutical companies are capitalist exploiters, a view also growing on the political right. That’s why Mr. Bancel is in the dock.
https://www.wsj.com/articles/bernie-sanders-moderna-stephane-bancel-covid-vaccine-price-6931a89a